Tumor Necrosis Factor and Colitis-Associated Colon Cancer  

Oleh:

Wilson, Joanne A.P.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 25 (Jun. 2008), page 2733.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Colon cancer is one of the most serious complications of chronic inflammatory bowel disease. The cumulative risk ranges from 2% among patients who have had colitis for 10 years to 18% among patients who have had colitis for 30 years.1 A clinical trial of infliximab, a humanized monoclonal antibody against tumor necrosis factor (TNF-), showed efficacy in the treatment of patients with moderate-to-severe ulcerative colitis.2 A recent study by Popivanova and colleagues3 sheds light on some of the molecular mechanisms that may underlie this therapeutic effect and suggests a role for anti–TNF- antibodies in the prevention of colitis-associated colon . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali